logo-loader
viewLexagene Holdings Inc.

Full interview: LexaGene working hard to manufacture genetic analyzer that can be used to detect Coronavirus

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Jack Regan tells Proactive the biotechnology company is working as hard as it can to get its diagnostic instrument that can be configured to detect threats like Coronavirus, into the hands of people who need it.

Regan also explained the problems with the current standard of testing for those who are infected with the virus.

Quick facts: Lexagene Holdings Inc.

Price: 0.83 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $71.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene hits milestone by having pre-commercial device in...

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Regan...

1 week ago

2 min read